News

Ligand Pharmaceuticals Sets Date for Q2 2025 Financial Update

Ligand Pharmaceuticals Sets Date for Q2 2025 Financial Update

Ligand Pharmaceuticals Plans Financial Results Announcement

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is preparing to report its financial results for the second quarter of 2025. The report is scheduled to be released on a Thursday in early August, kicking off a day designed for investors and analysts to gain insight into the company's performance and strategies moving forward.

Conference Call Details

On the same day as the financial report, Ligand will host a conference call at 8:30 AM Eastern Time. This call serves as an opportunity for the management team to discuss the results in-depth and share broader updates on the business operations of Ligand. Investors and interested parties are encouraged to participate in this informative session.

How to Access the Call

Those wishing to tune into the conference call can do so by dialing the following numbers: (800) 715-9871 for callers within the U.S. and Canada and (646) 307-1963 for international participants. When prompted, use the Conference ID 3661098 to gain access. Additionally, live webcasts of the call will be available, enhancing accessibility for all stakeholders.

Understanding Ligand's Business Model

Ligand Pharmaceuticals is recognized in the biopharmaceutical sector for its unique approach to enabling scientific progression. The company funds and supports the development of high-value medications through an innovative business model that focuses on licensing and financing. This strategy aims to create a diversified portfolio of revenue streams from biotechnology and pharmaceutical products.

Innovative Technology Platforms

Central to Ligand's success are its distinctive technology platforms, including the well-known Captisol® system. This platform is designed to enhance the solubility and stability of various drugs, making it a vital tool in their arsenal. Furthermore, the NITRICIL™ platform gives Ligand the ability to produce formulations that can adjust dosage over time, which is essential for addressing a wide range of medical conditions.

Partnerships with Leading Pharma Companies

Ligand has forged strong alliances with top-tier pharmaceutical firms such as Amgen, Merck, and Pfizer, among others. By leveraging the strengths of these industry leaders in late-stage development and commercialization, Ligand is positioned to maximize its revenue potential while minimizing operational costs.

Investor Engagement and Communication

Effective communication with investors is a priority for Ligand Pharmaceuticals. The company utilizes its investor relations webpage alongside its social media platforms to disseminate essential information to stakeholders. Ligand encourages investors to stay updated through its official website, social media accounts, SEC filings, and conference calls, fostering transparency and engagement.

Contact Information for Stakeholders

For inquiries, Ligand provides direct contact methods. Investors can reach out to Melanie Herman via email at investors@ligand.com or by calling (858) 550-7761. Media contacts are also available, with Kellie Walsh reachable at media@ligand.com and phone number (914) 315-6072.

Frequently Asked Questions

When will Ligand Pharmaceuticals announce its Q2 2025 financial results?

Ligand is set to announce its financial results for the second quarter of 2025 on August 7.

What time is the conference call scheduled?

The conference call will take place at 8:30 AM Eastern Time on the same day as the financial results announcement.

How can I participate in the conference call?

Participants can join by calling (800) 715-9871 for U.S. and Canadian callers or (646) 307-1963 for international callers, using the Conference ID 3661098.

What technologies does Ligand Pharmaceuticals specialize in?

Ligand is known for its Captisol® and NITRICIL™ platforms, which enhance drug solubility and allow adjustable dosing options respectively.

Who are some of Ligand's partners in the pharmaceutical industry?

Ligand collaborates with leading companies such as Amgen, Merck, and Pfizer to leverage their capabilities in drug development and commercialization.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 176

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 195

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 24

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 235

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

Cameco Prepares for Leadership Transition at Westinghouse Electric

Updated Category News Views 149

Cameco Acknowledges Leadership Changes at Westinghouse Cameco (TSX: CCO; NYSE: CCJ) has made a significant acknowledgment regarding the leadership transition at Westinghouse Electric Company. This moment marks a pivotal change as Patrick Fragman announces his decision to step down from his role as President and CEO of Westinghouse. Effective March 31, 2025, Patrick will...

Continue Reading
Discover Innovations at Taiwan Innotech Expo 2025 in AI

Updated Category News Views 296

Taiwan Innotech Expo 2025 Highlights The Taiwan Innotech Expo (TIE) is set to showcase the critical role of artificial intelligence (AI) in transforming various industries. Hosted in Taipei, this annual event brings together influential government agencies, including the Ministry of Economic Affairs and the National Science and Technology Council. The expo will open its...

Continue Reading
Explore Antarctica: A Unique Journey with Atlas Ocean Voyages

Updated Category News Views 225

Unveiling a Unique Antarctic Adventure Atlas Ocean Voyages, known for its intimate luxury expeditions, is set to elevate its offerings with a remarkable new program on board the luxury ship, World Traveller. This journey promises to provide guests not only breathtaking landscapes but also enriching experiences through collaboration with renowned photographer Karim Iliya...

Continue Reading
atNorth's Bold Expansion: Norway Meets Mega Data Site

Updated Category News Views 48

Setting the Stage in Haugaland Here's a bold move from atNorth that's got folks talking. This Nordic heavyweight isn't just dancing around the edges; they're making a big splash by staking their claim in Norway with a mega site that’s got ‘future’ written all over it. We’re talking a data center in Haugaland, starting with 120MW and aiming for a solid 350MW once...

Continue Reading
Volvo Group's CES Keynote: Paving the Path to Sustainability

Updated Category News Views 192

Volvo Group Spearheads Sustainability at CES At CES, the Consumer Electronics Show, Volvo Group’s President and CEO, Martin Lundstedt, captured the audience with a strong call to action regarding the future of transportation and infrastructure. Lundstedt emphasized the dire need for urgent changes in the industry to combat climate change, setting the tone for a vibrant...

Continue Reading